Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.
Wu SG, Ho CC, Yang JC, Yu SH, Lin YF, Lin SC, Liao BC, Yang CY, Lin YT, Yu CJ, Chuang YT, Liao WY, Yap KY, Kou WS, Shih JY.
Wu SG, et al. Among authors: lin yf, lin sc, lin yt.
Clin Transl Med. 2025 Jan;15(1):e70149. doi: 10.1002/ctm2.70149.
Clin Transl Med. 2025.
PMID: 39715697
Free PMC article.
Clinical Trial.